Evidence map›Paper›PMID 26012474›Full record

Trial reportCardiovascular ultrasound2015

The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI.

Jelena Kostic, Ana Djordjevic-Dikic, Milan Dobric, Dejan Milasinovic, Milan Nedeljkovic, Sinisa Stojkovic, Jelena Stepanovic, Milorad Tesic, Zoran Trifunovic, Danijela Zamaklar-Tifunovic and 3 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular ultrasound, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03445728 (Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03445728 phase4completednot on this mapstarted 2018, after this paper: background citation

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

TypeinterventionalSponsorChinese PLA General HospitalRan2018 to 2021Enrolled238ConditionsMyocardial Infarction, Percutaneous Coronary Intervention, NicorandilArmsNicorandil, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention.Medical science monitor : international medical journal of experimental and clinical research · 2017
    Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary intervention.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2020
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jelena KosticClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. jesikakostic@yahoo.com.
Ana Djordjevic-DikicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. skali.ana7@gmail.com.
Milan DobricClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. iatros007@gmail.com.
Dejan MilasinovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. dejan_milasinovic@yahoo.com.
Milan NedeljkovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. milanned@hotmail.com.
Sinisa StojkovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. sstojkovi@open.telekom.rs.
Jelena StepanovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. jelena.stepanovic@kcs.ac.rs.
Milorad TesicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. misa.tesic@gmail.com.
Zoran TrifunovicMilitary Medical Academy, Belgrade, Serbia. drtrifun@yahoo.com.
Danijela Zamaklar-TifunovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. danijelatrif@gmail.com.
Mina Radosavljevic-RadovanovicClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. radovanovicn@sbb.rs.
Miodrag OstojicMedical School, University of Belgrade, Belgrade, Serbia. mostojic2011@gmail.com.
Branko BeleslinClinic for Cardiology, Clinical Center of Serbia, Visegradska 26, Belgrade, Serbia. branko.beleslin@gmail.com.
Centar za Promociju Nauke · RSUniversity of Belgrade · RSMilitary Medical Academy · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNicorandil, as a selective potassium channel opener, has dual action including coronary and peripheral vasodilatation and cardioprotective effect through ischemic preconditioning. Considering those characteristics, nicorandil was suggested to reduce the degree of microvascular dysfunction.

methodsThirty-two patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI) were included in the study. Index of microvascular resistance (IMR) was measured in all patients immediatelly after pPCI before the after administration of Nicorandil. ST segment resolution was monitored before intervention and 60 min after terminating the procedure. Echocardiographic evaluation of myocardial function and transthoracic Doppler derived Coronary flow reserve (CFR) of infarct related artery (IRA) was performed during hospitalization and 3 months later.

resultsIMR was significantly lower after administration of Nicorandil (9.9 ± 3.7 vs. 14.1 ± 5.1, p < 0.001). There was significant difference in ST segment elevation before and after primary PCI with administration of Nicorandil (6.9 ± 3.7 mm vs. 1.6 ± 1.6 mm, p < 0.001). Transthoracic Doppler CFR measurement improved after 3 months (2.69 ± 0.38 vs. 2.92 ± 0.54, p = 0.021), as well as WMSI (1.14 ± 0.17 vs. 1.07 ± 0.09, p = 0.004).

conclusionIntracoronary Nicorandil administration after primary PCI significantly decreases IMR, resulting in improved CFR and ventricular function in patients with STEMI undergoing primary PCI.

Indexed as

Cardiotonic AgentsCoronary Artery DiseaseFemaleHumansMaleMicrocirculationMiddle AgedMyocardial InfarctionNicorandilPercutaneous Coronary InterventionTreatment OutcomeUltrasonographyCardiotonic AgentsNicorandil

Identifiers

PMID26012474
PMCPMC4446834
OpenAlexW1573015905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.